In vivo Evaluation of Cenderitide-Eluting Stent (CES) II

Area of Science:

• Biomedical Engineering
• Cardiovascular Research
• Drug Delivery Systems

Background:

• Drug-eluting stents (DES) reduce restenosis but delay endothelialization, requiring prolonged anti-thrombotic therapy.
• Cenderitide (CD-NP) is a novel anti-proliferative peptide that inhibits smooth muscle cells more than endothelial cells in vitro.
• Developing effective stent coatings is crucial for improving cardiovascular outcomes.

Purpose of the Study:

• To evaluate the in vivo efficacy of cenderitide-eluting stents (CES) in preventing in-stent restenosis (ISR) and promoting endothelialization.
• To assess the safety and drug release profile of CES in a porcine model.
• To compare CES performance against bare metal stents (BMS) and polymer-coated stents.

Main Methods:

• CES were fabricated by coating bare metal stents with CD-NP in poly(ε-caprolactone) using ultrasonic spray coating.
• 32 CES were implanted in 16 pigs, with survival assessed over 28 days.
• Plasma CD-NP levels, endothelial coverage (SEM), and histological parameters (inflammation, fibrin, neointimal area) were analyzed.

Main Results:

• Plasma CD-NP levels were significantly higher in the CES group post-stenting, confirming in vivo drug release.
• SEM analysis revealed significantly greater endothelial coverage on CES compared to controls.
• Histological examination showed mild inflammation and low fibrin scores in the CES group at 28 days.

Conclusions:

• Cenderitide-eluting stents demonstrate enhanced endothelialization and reduced inflammation in a porcine model.
• Despite improved healing, CES did not significantly reduce neointimal area or stenosis compared to BMS at 28 days.
• Further investigation is needed to optimize CES for improved anti-restenotic efficacy.